Showing results (221-230 of 235) with videos related to

Sort By:
Pageof 24
Nanoscale|August 6, 2015
Controlling molecular ordering in solution-state conjugated polymersJ Zhu, Y Han, R Kumar, et al.
Connective Tissue Research|January 1, 1990
Changes in vascular extracellular matrix accumulation reflect phenotypic differences between the arterial wall of pigeons resistant and susceptible to the development of spontaneous atherosclerosisH S Park, A C Kniep, S C Smith, et al.
Nanoscale|August 10, 2018
Synthesis, optical properties and theoretical modelling of discrete emitting states in doped silicon nanocrystals for bioimagingB F P McVey, D König, X Cheng, et al.
Circulation|September 1, 1995
Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement InvestigatorsG A Lamas, G C Flaker, G Mitchell, et al.
Psychological Medicine|December 21, 2006
Development of a new measure of health-related quality of life for people with dementia: DEMQOLS C Smith, D L Lamping, S Banerjee, et al.
Contraception|July 1, 1982
Effects of oral contraception on liver function tests and serum proteins in women with past viral hepatitisM M Shaaban, W A Hammad, M F Fathalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2002
Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancerB T Brett, S C Smith, C V Bouvier, et al.
AJNR. American Journal of Neuroradiology|July 25, 2015
Effects of Type 2 Diabetes on Brain Structure and Cognitive Function: African American-Diabetes Heart Study MINDC T Whitlow, K M Sink, J Divers, et al.
Circulation|March 18, 1997
When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk ReductionS M Grundy, G J Balady, M H Criqui, et al.
Pharmacology, Biochemistry, and Behavior|March 13, 2017
Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effectsJ M Witkin, J A Monn, J Li, et al.
Pageof 24